Search term:

Directory A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z Abcam Acambis Activotec ARM Holdings Alizyme Autonomy Amino Technologies AVEVA ARKeX Astex Therapeutics Abingworth Management Antenova ARTVPS Akubio Amadeus Capital ANT plc APR Smartlogik Avlar BioVentures Amura Accipia Azuro AVIT Research Asymptote Active Hotels Analysys Accelrys Artimi Antics Technology Astron Clinica Adder Technology AdventIQ Acaris Antitope Advance Nanotech Alphamerix ASM Scientific Axxcelera Arakis Arachnova Amgen Auriplex aIDEAS

Top 20 Companies Abcam Acambis Alizyme Amino Technologies ARM Holdings Autonomy AVEVA Bango Brady Celsis CSR Dialight Domino Printing Intercytex Meldex Minster Pharmaceuticals nCipher NXT Phytopharm Xaar

Previous articles

Tough year on the stock market for Silicon Fen's Top Ten but Autonomy sparkles

Briefs: New MD for St John’s Innovation Centre; Amino completes £1.4m takeover of AssetHouse

nCipher sees silver linings as SafeNet abandons its bid

CSR reports strong finish to 07, but the market is unimpressed

Clinical Cell Culture records lower revenue, wider losses in 2007: sees positive changes taking hold

Minster Pharma grows R&D spend in ‘06/07 as momentum in clinical trials builds

Domino Printing buys On-Line Coding Ltd for £300,000

News briefs: UK email off the mark in customer service; Malaysia seeks to emulate Silicon Fen

Tight US pharma research market prompts Sareum into ‘strategic review’

After a tough year MMI raises £1m; reports narrower losses; to change name to reflect new strategy

Subscribe

 

Corporate profiles

 • Delta G

Geraldine Rodgers Director

Delta G is a new company discovering and developing treatments for age-related disease. Founded in 2002, it received seed investment of £130,000 in 2004, and is now carrying out research in collaboration with the Medical Research Council. Delta G's principle research programme is in cancer therapeutics,

[Delta G's profile]

Top20 Index

Currently: 111.35